Grey Wolf

News

Immuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase tumour visibility.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.